Abivax SA ADR (ABVX)
NASDAQ: ABVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABVX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.41B
- EPS (TTM)
- -$6.08
- Dividend yield
- None
- 52-week range
- 62.70 – 148.83
- Day range
- 62.97 – 79.74
- Volume / Avg
- 14.85M / 1.35M
- Beta
- —
- Shares outstanding
- 87.54M
- Next earnings
- Dec 21, 2026
52-week range
ABVX stock today
Abivax SA (ABVX) closed at $73.20 on Nov 20, down 9.24% (-$7.45), versus the S&P 500's 3.70% decline. Volume was 11.0x the average at 14.85M shares, a sign of unusually heavy trading. Shares are 50.8% below their 52-week high of $148.83, set on Dec 24, 2025 and 16.7% above the 52-week low of $62.70, near the bottom of the past year's range.
ABVX is down 45.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.5%. Abivax SA has posted a net loss over the last twelve months (EPS of -$6.08), so its P/E ratio is not meaningful. Abivax SA's next earnings report is expected on Dec 21, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Abivax SA
Company profileABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marc M. P. de Garidel M.B.A.
- Headquarters
- Paris
- Employees
- 98
- IPO year
- 2023
- Website
- abivax.com
Analyst forecast
ForecastConsensus (12 analysts)
none
Avg. price target
$163.58+123.47%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 21, 2026
- EPS estimate
- $-1.27
ABVX news
All ABVX news- Abivax Statement on Short Seller ReportGlobeNewswire
- Abivax publie une déclaration concernant le rapport d'un vendeur à découvertGlobeNewswire
- Abivax to Participate in Upcoming Fall Investor ConferencesGlobeNewswire
- Abivax participera à plusieurs conférences investisseurs cet automneGlobeNewswire
- Notable ETF Inflow Detected - VEA, GFL, ABVX, SHOPNasdaqVEA, GFL, ABVX, SHOP
- Vanguard FTSE Developed Markets ETF Experiences Big InflowNasdaqVEA, BWLP, GFL, ABVX
Abivax SA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MIRMMirum Pharmaceuticals Inc. | 96.13 | +0.65% | $6.28B | vs ABVX |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs ABVX |
| SUPNSupernus Inc. | 28.61 | +0.92% | $5.94B | vs ABVX |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs ABVX |
| ARWRArrowhead Pharmaceuticals Inc. | 41.37 | -5.22% | $5.85B | vs ABVX |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs ABVX |
| LGNDLigand Pharmaceuticals Incorporated | 286.85 | -0.03% | $5.74B | vs ABVX |
| GRFSGrifols S.A. ADR | 8.15 | -0.61% | $5.55B | vs ABVX |
Indexes, lists and sector
Abivax SA stock FAQ
What is Abivax SA's stock price today?
ABVX last traded at $73.20 as of Nov 20, 4:00 PM EST, down 9.24% on the day. Prices are delayed at least 15 minutes.
When is Abivax SA's next earnings date?
Abivax SA is expected to report earnings on Monday, December 21, 2026. Analysts expect EPS of $-1.27.
Who is Abivax SA's CEO?
Mr. Marc M. P. de Garidel M.B.A. is the chief executive officer of Abivax SA ADR, which has about 98 employees.
What is the ABVX 52-week high?
The 52-week high for ABVX is $148.83 and the 52-week low is $62.70. The stock is currently 50.8% below its high.